title: Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment.
abstract: Metallothionein (MT) has been shown to have pro-proliferative anti-apoptotic activity and to be involved in microenvironment remodeling. The aim of this study has been to determine whether the changes in MT and vimentin immunoreactivity observed in cancer and its microenvironment are related to the local spread of the disease. The immunoreactivity levels of both MT and vimentin were evaluated together with CD56 and CD57 antigens in 49 tissue samples taken from patients with squamous cell carcinoma originating from the palatine tonsils and in 20 tissue samples derived from patients with chronic tonsillitis (the reference group). MT immunoreactivity levels were statistically significantly higher in the tissue samples from squamous cell carcinoma than in those of the reference group and also higher in the squamous cell carcinoma samples compared with the stromal samples. Moreover, stromal fibroblasts exhibited high vimentin and MT immunoreactivity levels. Statistically significantly higher MT immunoreactivity levels within the tumor cells were identified in patients with the presence of lymph node metastases in contrast to those patients without such metastases. Vimentin was detected in both the tumor and the stromal tissue samples and presented an interesting pattern of staining strongly expressed within the stroma and the septal architecture of the tumor. The number of CD56- and CD57-positive lymphocytes identified in tissue samples both from squamous cell carcinoma and from the stroma was statistically significantly lower than that in the reference group. MT expression by tumor cells is thus associated with an aggressive phenotype of the tumor and the ability to create metastases.
authors: Outpatient Unit of Otolaryngology, Lukaszczyk Oncological Center, Bydgoszcz, Poland. mowicher@gmail.com
authors: Magdalena
authors: M
authors: Dutsch-Wicherek
authors: Agata
authors: A
authors: Lazar
authors: Romana
authors: R
authors: Tomaszewska
authors: Wojciech
authors: W
authors: Kazmierczak
authors: Lukasz
authors: L
authors: Wicherek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000378:metabolism*; D006801:Humans; D008297:Male; D008668:Metallothionein / Q000032:analysis* / Q000378:metabolism; D008875:Middle Aged; D010610:Pharyngeal Neoplasms / Q000378:metabolism*; D000077195:Squamous Cell Carcinoma of Head and Neck; D014746:Vimentin / Q000032:analysis* / Q000378:metabolism
chemical_list: D014746:Vimentin; D008668:Metallothionein
references: J Immunol. 1996 Nov 1;157(9):3886-92
references: 8892619
references: Neuro Endocrinol Lett. 2006 Dec;27(6):786-94
references: 17187007
references: Cell. 2005 May 6;121(3):335-48
references: 15882617
references: Toxicology. 1996 Apr 15;108(1-2):129-40
references: 8644111
references: Cell Mol Life Sci. 2011 Sep;68(18):3033-46
references: 21637948
references: N Engl J Med. 1986 Dec 25;315(26):1650-9
references: 3537791
references: BMC Immunol. 2005 Sep 15;6:21
references: 16164753
references: Cancer Microenviron. 2010 Dec 15;4(1):105-13
references: 21505565
references: Cancer Cell. 2007 Dec;12(6):559-71
references: 18068632
references: J Cell Physiol. 2007 Nov;213(2):374-83
references: 17680632
references: Histochem Cell Biol. 2008 Dec;130(6):1091-103
references: 18987874
references: Cell Mol Biol (Noisy-le-grand). 2000 Mar;46(2):347-56
references: 10774924
references: Toxicol Sci. 2001 Jul;62(1):61-70
references: 11399794
references: Prostate. 2006 Nov 1;66(15):1664-73
references: 16902972
references: Acta Otolaryngol Suppl. 1997;527:25-9
references: 9197476
references: Front Biosci. 2008 May 01;13:4029-38
references: 18508497
references: Clin Exp Immunol. 1994 Sep;97(3):522-7
references: 7521809
references: Histopathology. 2004 Aug;45(2):103-18
references: 15279628
references: Neuro Endocrinol Lett. 2005 Oct;26(5):567-74
references: 16264399
references: Cancer Res. 2001 Nov 15;61(22):8135-42
references: 11719442
references: Br J Cancer. 2000 Mar;82(6):1198-203
references: 10735506
references: Cancer Microenviron. 2009 Dec;2(1):49-57
references: 19424824
references: Eur J Cancer. 1997 Oct;33(11):1860-4
references: 9470847
references: Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65
references: 12923528
references: Annu Rev Pharmacol Toxicol. 1999;39:267-94
references: 10331085
references: Cancer Microenviron. 2009 Sep;2 Suppl 1:9-17
references: 19701697
references: Mutat Res. 2003 Dec 10;533(1-2):201-9
references: 14643421
references: Clin Exp Immunol. 1995 Oct;102(1):159-66
references: 7554383
references: Mol Cancer Ther. 2008 Sep;7(9):2894-903
references: 18790770
references: Eur Arch Otorhinolaryngol. 1993;250(2):105-9
references: 7685179
references: Annu Rev Immunol. 2004;22:745-63
references: 15032595
references: J Pathol. 2003 Jul;200(4):429-47
references: 12845611
references: Clin Cancer Res. 2004 Jun 1;10(11):3755-62
references: 15173082
references: Cell Tissue Res. 2011 Sep;345(3):405-14
references: 21845402
references: Toxicol Sci. 2003 Jun;73(2):294-300
references: 12700406
references: Am J Physiol. 1999 Jul;277(1):C1-9
references: 10409103